

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **VENTUREPHARM LABORATORIES LIMITED**

**萬全科技藥業有限公司\***

*(incorporated in the Cayman Islands with limited liability)*  
**(Stock Code:8225)**

### **POSTPONMENT OF BOARD MEETING, DELAY IN PUBLICATION OF ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2013 AND SUSPENSION OF TRADING**

Reference is made to the announcement of Venturepharm Laboratories Limited (the “Company”) dated on 20<sup>th</sup> March 2014 in relation to the date of meeting (the “Board meeting”) of the board (the “Board”) of directors (the “directors”) of the Company for the purpose of considering and approving, among other matters, the audited consolidated financial results of the company and its subsidiaries for the year ended 31 December 2013 (the “Results”) and the draft announcement in respect of the results to be published on the GEM website.

As our auditors need more time to complete the auditing work, so the meeting originally dated on 31 March 2014 will be postponed, the meeting date will be announced separately. Accordingly, there will be a delay in the publication of the annual results announcement for the year 2013.

At the request of the company, trading in the securities of the company on the Stock Exchange will be suspended from 9:00 a.m. on 1 April 2014, and will remain suspended until the release of an announcement relating to the publication of its annual results and

dispatch of its annual report for the year ended 31 December 2013.

By order of the Board  
Venturepharm Laboratories Limited  
William Xia Guo  
Chairman

Beijing, the PRC, 28 March 2014

*\* For identification purpose only*

*As at the date of this announcement, the Board comprises two executive directors, being Mr. William Xia Guo and Dr. Maria Xue Mei Song; three non-executive directors, being Mr. Feng Tao, Mr. Li Jin Liang and Dr. Nathan Xin Zhang; and three independent non-executive directors, being Dr. Zhang Jing An, Mr. Paul Contomichalos and Dr. Wu Shou Yuan.*

*This announcement, for which the directors of the Company (the “Directors”) collectively and individually accept responsibility, includes particulars given in compliance with the Rules Governing the Listing of securities of the Growth Enterprise Market of the Stock Exchange for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, conform that, to the best of their knowledge and belief: (1) the information contained in this announcement is accurate and complete in all material respect and not misleading; (2) there are no other matters the omission of which would make any statement in all material respects and not misleading; and (3) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.*

*This announcement will remain on the GEM website with the domain name of [www.hkgem.com](http://www.hkgem.com) on the “Latest Company Announcements” page for at least 7days from the date of its posting and on the Company’s website at [www.venturepharm.com](http://www.venturepharm.com).*